IBEX 35
11.087,20 -18,30 (-0,16%) Euro Stoxx 50
5.073,78 -11,30 (-0,22%) Dólar/Euro
1,0799 +0,0027 (+0,25%) Petróleo Brent
83,32 +0,53 (+0,64%) Oro
2.352,90 -22,10 (-0,93%) Bitcoin EUR
58.124,88 +1.555,18 (+2,75%)
Amphastar Pharmaceuticals, Inc. (AMPH)
Antes de la apertura:
Amphastar Pharmaceuticals, Inc.
11570 6th Street
Rancho Cucamonga, CA 91730
United States
909 980 9484
https://www.amphastar.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1761
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ziping Luo Ph.D. | Chairman of the Board, Chief Scientist & COO | 1,36M | N/A | 1950 |
| Dr. Yongfeng Zhang Ph.D. | Co-Founder, President, CEO, Chief Scientific Officer & Director | 2M | N/A | 1947 |
| Mr. William J. Peters M.B.A. | CFO, Executive VP of Finance, Treasurer & Director | 1,21M | 7,17M | 1968 |
| Mr. Jacob Liawatidewi M.B.A. | Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director | 880,1k | 1,45M | 1974 |
| Mr. Rong Zhou M.S. | Senior Executive Vice President of Production | 962,3k | 997,35k | 1959 |
| Dan Dischner M.B.A. | Vice President of Human Resources & Corporate Communication | N/A | N/A | N/A |
| Tony Marrs M.B.A., M.P.H. | Senior VP of Regulatory Affairs & Clinical Operations | N/A | N/A | N/A |
Descripción
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Gobierno corporativo
El ISS Governance QualityScore de Amphastar Pharmaceuticals, Inc., a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 5; Tablero: 9; Derechos de los accionistas: 5; Compensación: 6.
